A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Latest Information Update: 05 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-412
- Sponsors Merck Sharp & Dohme
- 05 Sep 2024 This trial has been completed in Belgium (Global end date: 21 Aug 2024).
- 21 Feb 2024 Planned End Date changed from 29 Jun 2024 to 16 Aug 2024.
- 07 Dec 2022 Planned End Date changed from 29 Jun 2023 to 29 Jun 2024.